Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 9/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619957 | 1.00 | PREP (0.37) | PREPPROKR1HRH1KCNH2HPGDS | |
| SCHEMBL26713454 | 0.88 | HPGDS (0.43) | HPGDSBRD4 | |
| SCHEMBL30074854 | 0.88 | HPGDS (0.43) | HPGDSBRD4 | |
| SCHEMBL29036539 | 0.88 | HPGDS (0.43) | HPGDSBRD4 | |
| SCHEMBL26620634 | 0.85 | PROKR1 (0.43) | PREPPROKR1HPGDSCYP8B1PTGDR | |
| SCHEMBL26620636 | 0.85 | PROKR1 (0.43) | PREPPROKR1HPGDSCYP8B1PTGDR | |
| SCHEMBL26619906 | 0.84 | TLR7 (0.39) | PROKR1CACNA2D1KMT2A | |
| SCHEMBL26619911 | 0.84 | TLR7 (0.39) | PROKR1CACNA2D1KMT2A | |
| SCHEMBL30074856 | 0.75 | CYP1A2 (0.39) | HPGDSCYP2D6MEN1KMT2A | |
| SCHEMBL26619757 | 0.75 | CYP1A2 (0.39) | HPGDSCYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348458-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348458-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | PREP 1969/4885PROKR1 2933/4885HRH1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.